The near-30% fall in listed cancer diagnostics company Pacific Edge’s share price so far this year is “unjustified” and “overdone”, Forsyth Barr analysts say.
And the company’s new chief executive Peter Meintjes has also flagged the company’s ailing share price in his first letter
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
